Article in Pediatric diabetes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 8 institutions in 1 country.
Lina MerjanehDepartment of Pediatrics, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-4769-5626
Lawrence M DolanDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Cynthia K SuerkenDepartment of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Ralph D'AgostinoDepartment of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Giuseppina ImperatoreDivision of Diabetes Translation, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Atlanta, Georgia, USA.
Sharon SaydahDivision of Diabetes Translation, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Atlanta, Georgia, USA.
Alissa RobertsDepartment of Pediatrics, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-0221-6273
Santica MarcovinaMedpace Reference Laboratories, Cincinnati, Ohio, USA.
Elizabeth J Mayer-DavisDepartments of Nutrition and Medicine, University of North Carolina at Chapel Hill, North Carolina, USA.ORCID 0000-0003-3858-0517
Dana DabeleaDepartment of Epidemiology, Colorado School of Public Health, University of Colorado Denver, Aurora, Colorado, USA.
Jean M LawrenceDivision of Diabetes, Endocrinology, and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-2480-8480
Catherine PihokerDepartment of Pediatrics, University of Washington, Seattle, Washington, USA.ORCID 0000-0001-9074-7770
University of Washington · USCenters for Disease Control and Prevention · USWake Forest University · USColorado School of Public Health · USMedpace (United States) · USNational Institutes of Health · USUniversity of Cincinnati Medical Center · USUniversity of North Carolina at Chapel Hill · US
Funding
Institute of Translational Health SciencesUL1TR000423 · NCATS · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2012 to 2016
$49.4M
South Carolina Clinical & Translational Research Institute (SCTR)UL1TR001450 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T., FLUME, PATRICK A · 2015 to 2024
$41.1M
LCenter for Clinical and Translational Science and TrainingUL1TR001425 · NCATS · UNIVERSITY OF CINCINNATI · PI MEINZEN-DERR, JAREEN, STRAWN, JEFFREY ROBERT · 2015 to 2024
$37.5M
Colorado Clinical and Translational Science Institute (UL1)UL1TR000154 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2012 to 2013
$20.4M
Limited Competition for the Continuation of the SEARCH for Diabetes in Youth Cohort Study (UC4)SEARCH for Diabetes in Youth Cohort StudyUC4DK108173 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI DAGOSTINO, RALPH B. · 2015 to 2016
$14.8M
UCHSC DIABETES ENDOCRINOLOGY RESEARCH CENTERP30DK057516 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI HUTTON, JOHN C · 2000 to 2010
$14.0M
Cincinnati Center for Clinical and Translational Sciences and TrainingUL1TR000077 · NCATS · UNIVERSITY OF CINCINNATI · PI HEUBI, JAMES E., TSEVAT, JOEL · 2012 to 2014
$9.9M
South Carolina Clinical & Translational Research Institute (SCTR)UL1TR000062 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2012 to 2014
$9.4M
SEARCH for Diabetes in Youth Coordinating CenterU01DP000250 · DP · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BELL, RONNY A · 2005 to 2009
$4.8M
Population-based Diabetes Youth RegistryU18DP006131 · DP · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI WAGENKNECHT, LYNNE E · 2015 to 2019
$3.8M
SEARCH For Diabetes in Youth, Phase 3: Cohort Study-Carolina CenterU18DP002708 · DP · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MAYER-DAVIS, ELIZABETH J · 2010 to 2014
$3.6M
SEARCH for Diabetes in Youth 2: Colorado CenterU01DP000247 · DP · UNIVERSITY OF COLORADO DENVER · PI DABELEA, DANA · 2005 to 2009
To assess changes in diabetes autoantibodies (DAs) over time in children and young adults with diabetes and determine whether observed changes were associated with demographic characteristics, clinical parameters and diabetes complications. Participants had DAs measured at baseline (10.3 ± 7.1 months after diabetes diagnosis) and at 12, 24 months and ≥5 years after the baseline measurement. At the ≥5-year follow-up, the presence of diabetes complications was assessed. We examined the associations between change in number of positive DAs and changes in individual DA status with the participants' characteristics and clinical parameters over time. Out of 4179 participants, 62% had longitudinal DA data and 51% had complications and longitudinal DA data. In participants with ≥1 baseline positive DA (n = 1699), 83.4% remained positive after 7.3 ± 2.3 years duration of diabetes. Decrease in number of positive DAs was associated with longer diabetes duration (p = 0.003 for 1 baseline positive DA; p < 0.001 for 2 baseline positive DAs) and younger age at diagnosis (p < 0.001 for 2 baseline positive DAs). No associations were found between change in number of positive DAs in participants with ≥1 baseline positive DA (n = 1391) and HbA1c, insulin dose, acute, or chronic complications after 7.7 ± 1.9 years duration of diabetes. DA status likely remains stable in the first 7 years after diabetes diagnosis. Younger age at diabetes diagnosis and longer duration were associated with less persistence of DAs. Measuring DAs after initial presentation may aid in diabetes classification but not likely in predicting the clinical course.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A longitudinal assessment of diabetes autoantibodies in the SEARCH for diabetes in youth study. · full record | OpenQuestion